DUBLIN , Aug. 23, 2022 /PRNewswire/ -- The "Rapid Acting Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global rapid acting insulin market size reached US$ 7 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 9.3 Billion by 2027, exhibiting a CAGR of 4.85% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor. Rapid acting insulin is a medication used to control glucose levels in patients with diabetes. It is either inhaled or administered into the bloodstream with a syringe, a pre-filled pen, or an insulin pump. It is taken prior to meals and snacks to bring overly high blood glucose to a normal level and surge the level of bolus insulin. At present, new insulin formulations like novel ultra-paid-acting insulins that enhance absorption are considered a suitable option for people who cannot achieve postprandial glycemic targets with other bolus insulins. Diabetes mellitus (DM) and poorly controlled blood glucose can increase the risk of mortality and severity among patients with coronavirus disease (COVID-19). This represents one of the key factors fueling the need for rapid acting insulins to monitor blood glucose levels.
Apart from this, the growing prevalence of type 1 diabetes on account of exposure to viruses and other environmental factors and low levels of vitamin D acts as another factor propelling the demand for rapid acting insulins across the globe. This can also be attributed to the increasing instances of neonatal jaundice in newborns, in confluence with improving diagnostic modalities. In addition to this, as the risk of developing diabetes increases with age, the rising global geriatric population is facilitating the market growth.
Furthermore, leading market players are introducing ready-to-use rapid acting insulin kits that are fast, accessible in vials and a pen presentation, and help enhance glycemic control in both adults and children. These players are also focusing on mergers and acquisitions (M&A), which is anticipated to contribute to the development of new-generation product variants.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd. Key Questions Answered in This Report:
How has the global rapid acting insulin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global rapid acting insulin market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global rapid acting insulin market and who are the key players?
What is the degree of competition in the industry?
Key Topics Covered: 1 Preface 2 Scope and Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Rapid Acting Insulin Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product 6.1 Lispro Insulin 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Aspart Insulin 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Glulisine Insulin 6.3.1 Market Trends 6.3.2 Market Forecast 7 Market Breakup by Indication 7.1 Type 1 Diabetes 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Type 2 Diabetes 7.2.1 Market Trends 7.2.2 Market Forecast 8 Market Breakup by Distribution Channel 8.1 Hospital Pharmacies 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Drug Stores and Retail Pharmacies 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Online Stores 8.3.1 Market Trends 8.3.2 Market Forecast 9 Market Breakup by Region 10 SWOT Analysis 11 Value Chain Analysis 12 Porters Five Forces Analysis
13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Adocia 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.2 Biocon Limited 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Eli Lilly and Company 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 Gan & Lee Pharmaceuticals Co. Ltd. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.5 Geropharm 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.6 MannKind Corporation 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 Merck & Co. Inc. 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.7.4 SWOT Analysis 14.3.8 Novo Nordisk A/S 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Sanofi S.A. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis 14.3.10 Wockhardt Ltd. 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials For more information about this report visit https://www.researchandmarkets.com/r/riou7z
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/9-3-billion-worldwide-rapid-acting-insulin-industry-to-2027---featuring-adocia-biocon-limited-and-geropharm-among-others-301610826.html
Federated Hermes Chief Equity Strategist Phil Orlando joins Yahoo Finance Live to discuss Jerome Powell's latest comments and what the next steps from the Fed may be to fight inflation.
Though signs point to prices moderating, Powell said on Friday that the bank will continue to hike interest rates this year
The Fed chair obviously chose to ignore data released just today that shows that current consumer level inflation is not exactly out of control.
The chip maker has lost a third of its value in 2022. Its CEO just made his biggest buy of shares since becoming CEO early last year.
Follow Buffett’s lead. And collect big dividends while you’re at it.
The old stock market axiom to buy when others are fearful could readily apply right now, according to Ashish Shah, chief investment officer at Goldman Sachs. Amid concerns markets will be volatile following Federal Reserve Chair Jerome Powell’s Jackson Hole policy speech on Friday, Shah thinks that doesn’t mean investors should stay on the sidelines at present. It's preferable to buy "when there's fear in the market," say Shah. "Don't fall into the trap of buying when there's FOMO," he added. Ag
Altria Group (MO) declares a dividend hike of 4.4%, taking its quarterly dividend to 94 cents per share. The company is focused on boosting shareholders' returns.
Nio (NYSE: NIO) investors got some good news from Chinese authorities for the second day in a row today. The company's American depositary shares are responding again this morning, jumping 6% at the market open but easing to a gain of 1.9% as of 10:05 a.m. ET. Shares of the Chinese EV company spiked yesterday on news that the Chinese government was adding a new stimulus package to jump-start a sagging economy.
Yahoo Finance's Ines Ferre breaks down Friday's market action, with stocks closing at the lows of the session and the U.S. dollar rising.
In this article, we discuss Bill Gates’ top 10 dividend stocks. You can skip our detailed analysis of the Bill & Melinda Gates Foundation’s performance, and go directly to read Bill Gates Portfolio: Top 5 Dividend Stock Picks. Bill & Melinda Gates Foundation was established in 2000 with the purpose to improve the well-being of […]
Yahoo Finance reporter Ines Ferre looks at how the stock market is reacting to Fed Chair Powell's speech at the Jackson Economic Hole Symposium.
Fed chief Jerome Powell warned Friday to expect some "pain," and the market rally certainly felt it. Here's what to do now.
High-yielding dividend stocks are great for income investors and are crucial to building a strong retirement portfolio.
Market participants have been concerned for weeks about what Federal Reserve Chair Jerome Powell might say at the central bank's annual symposium in Jackson Hole. Apparently, they were quite discouraged by what they heard, as Powell restated the Fed's determination to push interest rates as high as they needed to go in order to ensure that inflationary pressures don't become permanently entrenched in the U.S. economy. Percentage drops for the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) were also in the 3% to 4% range.
The news is good for some — but not for others.
What company is next to split its shares after Tesla? There's one logical answer hiding in plain sight.
Beijing offered a rare concession Friday, agreeing to allow U.S. accounting regulators to examine the audits of Chinese firms listed on American stock exchanges.
Wells Fargo Head of Global Asset Allocation Strategy Tracie McMillion and Westwood Quality Value Fund Head of US Value and PM Matt Lockridge join Yahoo Finance Live to discuss Chair Powell's speech, the state of the U.S. economy, the labor market, and opportunities in the market.
Here's why one Wall Street analyst really loves Peloton's stock.
As U.S. stocks head for their biggest daily drop in more than two months, it appears equities were the last asset class to accept the notion that the Federal Reserve likely won't be pivoting to a less aggressive monetary policy stance --- at least not any time soon.